V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10435119 | 10041732 | 1.72 | 79 | Curative (C) | null | 2019-10-05 | null | null | null | CISPLATIN + CYCLOPHOSPHAMIDE + CYTARABINE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 101095777 |
| 10435233 | 10041733 | 1.6 | 69.45 | Neo-adjuvant (N) | 2017-02-15 | 2017-03-13 | Paclitaxel+Trastuzumab wkly Maint | N | null | BEXAROTENE | 101597282 |
| 10435249 | 10041734 | 1.83 | 69.9 | Palliative (P) | 2018-12-27 | 2019-01-04 | null | 02 | null | BENDAMUSTINE + OBINUTUZUMAB | 101044012 |
| 10435267 | 10041735 | 1.79 | 62 | Palliative (P) | 2019-01-02 | 2019-01-02 | Bortezomib + MELPHALAN | 02 | null | RADIUM 223 | 100581166 |
| 10435409 | 10041738 | 1.67 | 43.9 | Curative (C) | null | 2019-04-09 | ABEMACICLIB + FULVESTRANT | N | null | CISPLATIN + CAPECITABINE + EPIRUBICIN | 101610498 |
| 10435428 | 10041739 | 1.62 | 80.7 | Adjuvant (A) | 2019-12-15 | 2019-12-17 | CARBOPLATIN + PACLITAXEL + RT | 02 | N | LETROZOLE + PALBOCICLIB | 101320532 |
| 10435479 | 10041740 | 1.6 | 76 | Palliative (P) | 2019-07-05 | 2019-07-06 | DHAP - R | 02 | N | AFATINIB | 101077852 |
| 10435670 | 10041742 | 1.54 | 100.6 | Palliative (P) | 2019-04-11 | 2019-04-16 | Fulvestrant + Palbociclib | 02 | N | CARBOPLATIN + DOCETAXEL + TRASTUZUMAB | 101299719 |
| 10435680 | 10041743 | 1.67 | 90 | Palliative (P) | 2019-06-17 | 2019-06-22 | TCH (21 day Trastuzumab) Maint | 02 | N | APALUTAMIDE | 100433817 |
| 10435766 | 10041745 | 1.65 | 85 | Palliative (P) | null | 2022-03-23 | CYCLOPHOSPHAMIDE + EPIRUBICIN + PACLITAXEL | 2 | null | PERTUZUMAB + TRASTUZUMAB | 101165781 |
| 10435795 | 10041746 | 1.78 | 88 | Neo-adjuvant (N) | 2017-01-25 | 2017-02-07 | null | 02 | null | GEMCITABINE + NAB-PACLITAXEL | 100345746 |
| 10435912 | 10041747 | 1.7 | 76 | Adjuvant (A) | null | 2019-11-13 | LENVATINIB | 01 | N | CISPLATIN + GEMCITABINE + RITUXIMAB | 101514335 |
| 10435981 | 10041750 | 1.76 | 75 | Neo-adjuvant (N) | 2019-07-18 | 2019-07-19 | Sorafenib | 02 | N | CAPECITABINE + RT | 101661322 |
| 10435985 | 10041751 | 1.65 | 95 | Disease modification (D) | 2020-01-29 | 2020-02-05 | ECX | 2 | N | OFATUMUMAB | 100678603 |
| 10436105 | 10041754 | 1.74 | 87.6 | Palliative (P) | 2017-11-26 | 2017-11-26 | VEPEMB | N | N | METHOTREXATE | 100367446 |
| 10436139 | 10041756 | 1.8 | 65.6 | 03 | 2020-01-02 | 2020-01-10 | Fulvestrant + Palbociclib | 02 | N | OXALIPLATIN + MDG | 100022520 |
| 10436240 | 10041757 | 1.57 | 0 | Palliative (P) | 2018-06-26 | 2018-07-02 | Bevacizumab | N | N | BEVACIZUMAB | 100342518 |
| 10436327 | 10041760 | 1.64 | 65.8 | Neo-adjuvant (N) | 2017-02-08 | 2017-02-15 | Atezolizumab | 02 | N | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 100789965 |
| 10436549 | 10041766 | null | 82.9 | null | 2019-10-12 | 2019-10-12 | EOX | 02 | null | CISPLATIN + CAPECITABINE + EPIRUBICIN | 100977403 |
| 10436566 | 10041767 | 1.85 | 0 | Palliative (P) | 2021-02-05 | 2021-03-05 | Bendamustine +/- Prednisolone | null | null | OSIMERTINIB | 100547553 |
| 10436587 | 10041768 | 1.8 | 75 | Palliative (P) | 2020-01-06 | 2020-01-28 | Ixazomib | 02 | N | THALIDOMIDE | 100490944 |
| 10436596 | 10041769 | 1.69 | 72.6 | 03 | 2019-09-10 | 2019-10-01 | OSIMERTINIB | 02 | N | CYCLOPHOSPHAMIDE + CYTARABINE + DOXORUBICIN + ETOPOSIDE + IFOSFAMIDE + METHOTREXATE + RITUXIMAB + VINCRISTINE | 100906489 |
| 10436631 | 10041770 | 1.69 | 67.2 | Curative (C) | 2019-02-26 | 2019-03-05 | AVELUMAB + AXITINIB | 02 | Y | CISPLATIN + RT | 100361871 |
| 10436659 | 10041771 | 1.83 | 72.6 | Palliative (P) | 2018-05-22 | 2018-05-22 | CYCLO + DOXORUBICIN + PACLITAXEL | 02 | N | CHLORAMBUCIL + PROCARBAZINE + VINBLASTINE | 100483441 |
| 10436743 | 10041772 | 0 | 64.9 | null | 2021-03-03 | 2021-03-12 | Letrozole + Palbociclib | 02 | null | FLUOROURACIL + MITOMYCIN + RT | 101524307 |
| 10436802 | 10041774 | 1.75 | null | Palliative (P) | 2021-09-19 | 2021-10-15 | AFATINIB | null | N | BEXAROTENE | 100628317 |
| 10436809 | 10041775 | null | null | Curative (C) | 2020-01-01 | 2020-01-06 | R CODOX M | N | N | CISPLATIN + CYCLOPHOSPHAMIDE + CYTARABINE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 100447395 |
| 10436827 | 10041777 | 1.71 | 65.6 | Curative (C) | null | 2018-01-10 | Apalutamide | 02 | N | LOMUSTINE + PROCARBAZINE + VINCRISTINE | 100696615 |
| 10436872 | 10041778 | 1.74 | 78.2 | null | null | 2022-02-09 | Obinutuzumab +CHOP | 02 | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + METHOTREXATE + RITUXIMAB + VINCRISTINE | 100898193 |
| 10436941 | 10041779 | 1.82 | 63.7 | Adjuvant (A) | 2020-01-10 | 2020-01-10 | Cisplatin + Docetaxel +Fluorouracil | 02 | N | CYTARABINE + DAUNORUBICIN | 101603365 |
| 10437075 | 10041782 | 1.71 | 69.9 | Curative (C) | 2017-01-12 | 2017-01-12 | ANAGRELIDE | 02 | N | AXITINIB | 100421334 |
| 10437192 | 10041786 | 1.69 | 73.5 | Adjuvant (A) | 2017-08-22 | 2017-08-24 | CHLORAMBUCIL + ETOPOSIDE + LOMUSTINE | 99 | N | LOMUSTINE + PROCARBAZINE + VINCRISTINE | 100214368 |
| 10437254 | 10041787 | 1.58 | 68.7 | Curative (C) | 2021-04-18 | 2021-04-18 | Cisplatin + Etoposide po&iv 3 day | 02 | N | CISPLATIN + CYCLOPHOSPHAMIDE + DOXORUBICIN | 101549065 |
| 10437314 | 10041788 | 1.73 | 71.2 | Curative (C) | 2021-06-03 | 2021-06-03 | Irinotecan + Modified De Gramont | 01 | null | BLEOMYCIN + DACARBAZINE + DOXORUBICIN + VINBLASTINE | 100545764 |
| 10437326 | 10041789 | null | null | Curative (C) | 2020-01-26 | 2020-02-08 | Doxorubicin + Olaratumab | 2 | null | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100374440 |
| 10437365 | 10041790 | null | 78.5 | Curative (C) | null | 2018-07-04 | GemCarbo Days 1+8 | null | N | EVEROLIMUS + EXEMESTANE | 101437045 |
| 10437439 | 10041791 | 1.73 | 83.8 | Disease modification (D) | null | 2019-12-07 | CARBOPLATIN + GEMCITABINE | N | N | CISPLATIN + EPIRUBICIN + FLUOROURACIL | 100583277 |
| 10437536 | 10041794 | null | null | Adjuvant (A) | 2018-05-09 | 2018-05-18 | ENRICH Trial | 02 | null | RIALTO TRIAL | 100113240 |
| 10437589 | 10041796 | 1.6 | 118.2 | Adjuvant (A) | 2018-08-09 | 2018-08-13 | AVELUMAB + AXITINIB | N | N | CISPLATIN + ETOPOSIDE | 100680739 |
| 10437595 | 10041797 | 1.77 | 100 | Curative (C) | 2018-03-16 | 2018-03-21 | CTD | 02 | N | IXAZOMIB + LENALIDOMIDE | 101320785 |
| 10437652 | 10041798 | 1.68 | 75 | Curative (C) | null | 2018-10-04 | MPT | null | null | CISPLATIN + RT | 100786468 |
| 10437674 | 10041799 | 1.8 | 65 | Curative (C) | 2018-03-11 | 2018-03-20 | null | 02 | N | CAPECITABINE + RT | 101766499 |
| 10437930 | 10041802 | 1.52 | 74.4 | null | 2018-11-04 | 2018-11-11 | DACARBAZINE + DOXORUBICIN + VINBLASTINE | 02 | null | FLUOROURACIL + MITOMYCIN + RT | 100881668 |
| 10437947 | 10041804 | 1.73 | 59 | Palliative (P) | 2020-05-12 | 2020-05-12 | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB | 01 | N | DOXORUBICIN EMBOLISATION | 100152227 |
| 10438009 | 10041806 | 0 | 79.3 | null | 2017-02-02 | 2017-02-23 | PLATO Trials | 2 | Y | MIDOSTAURIN | 100620807 |
| 10438010 | 10041807 | null | null | Neo-adjuvant (N) | 2019-07-24 | 2019-07-25 | LANREOTIDE | N | N | BEXAROTENE | 100272352 |
| 10438141 | 10041808 | 1.67 | 61.8 | 03 | 2021-06-07 | 2021-06-14 | GEMCITABINE + NAB PACLITAXEL | 02 | N | CARBOPLATIN + LIPOSOMAL DOXORUBICIN | 101511436 |
| 10438175 | 10041809 | 0 | 94 | 03 | null | 2020-01-12 | null | null | null | GEMCARBO | 100088426 |
| 10438188 | 10041810 | 1.67 | 81.3 | Curative (C) | 2021-09-21 | 2021-09-21 | GEMCITABINE + NAB PACLITAXEL | 02 | null | AZACITIDINE + VENETOCLAX | 100720749 |
| 10438314 | 10041811 | 1.75 | 73.6 | Palliative (P) | 2019-09-07 | 2019-09-17 | BEVACIZUMAB + CARBO + PACLITAXEL | 02 | N | LUTETIUM-177 | 100958475 |